The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Ironwood Pharmaceuticals Inc

Nasdaq: IRWD
Last

(U.S.) $16.00

Today's change0.00 0.00%
Updated March 31 4:00 PM EDT. Delayed by at least 15 minutes.
 

Ironwood Pharmaceuticals Inc

Nasdaq: IRWD
Last

(U.S.) $16.00

Today's change0.00 0.00%
Updated March 31 4:00 PM EDT. Delayed by at least 15 minutes.

Ironwood Pharmaceuticals Inc closed at (U.S.)$16.00.

Shares have lost 0.68% over the last five days, but have gained 4.44% over the last year to date. This security has outperformed the S&P 500 by 19.43% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $16.00
  • High--
  • Low--
  • Bid / Ask(U.S.) $0.00 / (U.S.) $19.00
  • YTD % change+4.44%
  • Volume0
  • Average volume (10-day)1,458,950
  • Average volume (1-month)1,085,335
  • Average volume (3-month)992,673
  • 52-week range(U.S.) $9.01 to (U.S.) $17.11
  • Beta1.41
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.39
Updated March 31 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-248.07%

Ironwood Pharmaceuticals Inc has a net profit margin of -248.07%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.04%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue3817715
Total other revenue--------
Total revenue3817715
Gross profit2517-413
Total cost of revenue130112
Total operating expense71546259
Selling / general / administrative31292930
Research & development27252227
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-33-37-55-44
Interest income (expense), net non-operating-5-5-5-5
Gain (loss) on sale of assets--------
Other--------
Income before tax-38-42-60-50
Income after tax-38-42-60-50
Income tax, total0000
Net income-38-42-60-50
Total adjustments to net income--------
Net income before extra. items-38-42-60-50
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-38-42-60-50
Inc. avail. to common incl. extra. items-38-42-60-50
Diluted net income-38-42-60-50
Dilution adjustment--000
Diluted weighted average shares140139138130
Diluted EPS excluding extraordinary itemsvalue per share-0.27-0.30-0.44-0.38
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.27-0.30-0.44-0.38